Conny Gysemans

Dr. Conny Gysemans

orcid

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 July 2010 in Cancer Research
Verified
Journal Article
Closed access
KMKiavash Movahedi
Kiavash Movahedi
DLDamya Laoui
Damya Laoui
CGConny Gysemans
Conny Gysemans
MBMartijn Baeten
Martijn Baeten
GSgeert stange
geert stange
JGJo A. Van Ginderachter
Jo A. Van Ginderachter
Tumor-associated macrophages (TAM) form a major component of the tumor stroma. However, important concepts such as TAM heterogeneity and the nature of the monocytic TAM precursors remain speculative. Here, we show for the first time that mouse mammary tumors contained functionally distinct subsets of TAMs and provide markers for their identification. Furthermore, in search of the TAM progenitors, we show that the tumor-monocyte pool almost exclusively consisted of Ly6ChiCX3CR1low monocytes, which continuously seeded tumors and renewed all nonproliferating TAM subsets. Interestingly, gene and protein profiling indicated that distinct TAM populations differed at the molecular level and could be classified based on the classic (M1) versus alternative (M2) macrophage activation paradigm. Importantly, the more M2-like TAMs were enriched in hypoxic tumor areas, had a superior proangiogenic activity in vivo, and increased in numbers as tumors progressed. Finally, it was shown that the TAM subsets were poor antigen presenters, but could suppress T-cell activation, albeit by using different suppressive mechanisms. Together, our data help to unravel the complexities of the tumor-infiltrating myeloid cell compartment and provide a rationale for targeting specialized TAM subsets, thereby optimally “re-educating” the TAM compartment. Cancer Res; 70(14); 5728–39. ©2010 AACR.

1 August 2010 in Current Opinion in Pharmacology
Verified
Journal Article
Closed access
FBFemke Baeke
Femke Baeke
TTTatiana Takiishi
Tatiana Takiishi
HKHannelie Korf
Hannelie Korf
CGConny Gysemans
Conny Gysemans
CMChantal Mathieu
Chantal Mathieu

15 April 2008 in Blood
Verified
Journal Article
Closed access
KMKiavash Movahedi
Kiavash Movahedi
MGMartin Guilliams
Martin Guilliams
Jan Van den BosscheJan Van den Bossche
Jan Van den Bossche
RBRafael Van den Bergh
Rafael Van den Bergh
CGConny Gysemans
Conny Gysemans
JGJo A. Van Ginderachter
Jo A. Van Ginderachter
The induction of CD11b+Gr-1+ myeloid-derived suppressor cells (MDSCs) is an important immune-evading mechanism used by tumors. However, the exact nature and function of MDSCs remain elusive, especially because they constitute a heterogeneous population that has not yet been clearly defined. Here, we identified 2 distinct MDSC subfractions with clear morphologic, molecular, and functional differences. These fractions consisted of either mononuclear cells (MO-MDSCs), resembling inflammatory monocytes, or low-density polymorphonuclear cells (PMN-MDSCs), akin to immature neutrophils. Interestingly, both MO-MDSCs and PMN-MDSCs suppressed antigen-specific T-cell responses, albeit using distinct effector molecules and signaling pathways. Blocking IFN-γ or disrupting STAT1 partially impaired suppression by MO-MDSCs, for which nitric oxide (NO) was one of the mediators. In contrast, while IFN-γ was strictly required for the suppressor function of PMN-MDSCs, this did not rely on STAT1 signaling or NO production. Finally, MO-MDSCs were shown to be potential precursors of highly antiproliferative NO-producing mature macrophages. However, distinct tumors differentially regulated this inherent MO-MDSC differentiation program, indicating that this phenomenon was tumor driven. Overall, our data refine tumor-induced MDSC functions by uncovering mechanistically distinct MDSC subpopulations, potentially relevant for MDSC-targeted therapies.

3 May 2009 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
LMLajos Mátés
Lajos Mátés
MCMarinee K L Chuah
Marinee K L Chuah
EBEyayu Belay
Eyayu Belay
BJBoris Jerchow
Boris Jerchow
NMNamitha Manoj
Namitha Manoj
ZIZsuzsanna Izsvák
Zsuzsanna Izsvák

22 June 2005 in Diabetologia
Verified
Journal Article
Closed access
PDF file
CMC. Mathieu
C. Mathieu
CGConny Gysemans
Conny Gysemans
AGA. Giulietti
A. Giulietti
RBR. Bouillon
R. Bouillon

28 April 2020 in Nutrients
Verified
Journal Article
Open access
PDF file
PMPieter-Jan Martens
Pieter-Jan Martens
CGConny Gysemans
Conny Gysemans
MVMieke Verstuyf
Mieke Verstuyf
CMChantal Mathieu
Chantal Mathieu
Ever since its discovery by Windhaus, the importance of the active metabolite of vitamin D (1,25-dihydroxyvitamin D3; 1,25-(OH)2D3) has been ever expanding. In this review, the attention is shifted towards the importance of the extra-skeletal effects of vitamin D, with special emphasis on the immune system. The first hint of the significant role of vitamin D on the immune system was made by the discovery of the presence of the vitamin D receptor on almost all cells of the immune system. In vitro, the overwhelming effect of supra-physiological doses of vitamin D on the individual components of the immune system is very clear. Despite these promising pre-clinical results, the translation of the in vitro observations to solid clinical effects has mostly failed. Nevertheless, the evidence of a link between vitamin D deficiency and adverse outcomes is overwhelming and clearly points towards avoidance of vitamin D deficiency especially in early life.